Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting Sara Marsal Barril, Mª Auxiliadora Martin-Martinez, Francisco Javier Blanco-Garcia, Antonio Fernández-Nebro, Rosario García de Vicuña, Jesús Tornero-Molina, Fernando Sánchez-Alonso, Marta Novella-Navarro, Alejandro Escudero-Contreras, Juan José Alegre-Sancho, Ana Urruticoechea-Arana, Maria Sagrario Bustabad-Reyes, Pilar Trenor-Larraz, Trinidad Pérez-Sandoval, Maria Isabel Tevar-Sánchez, Jesús T. Sánchez-Costa, Enrique Raya-Álvarez

Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice Jordi Gratacós-Masmitja, Emma Beltrán Catalán, José Luis Álvarez Vega, Ana Urruticoechea-Arana, Concepción Fito, Francisco Maceiras, Joaquín María Belzunegui Otano, Julia Fernández Melón, Eugenio Chamizo Carmona, Miguel Ángel Abad Hernández, Inmaculada Ros Vilamajó, Sonia Castro Oreiro, Eva Pascual Alfonso, Juan Carlos Torre Alonso

Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study Pilar Espiño-Lorenzo, Sara Manrique-Arija, Inmaculada Ureña, Francisco Gabriel Jiménez-Núñez, María López-Lasanta, Carmen María Romero-Barco, María Angeles Belmonte-López, María Victoria Irigoyen, Antonio Fernández-Nebro